Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255044 | 0.87 | KDM4E (0.57) | RIPK1KDM4ECYP2C19HCRTR2TP53 | |
| SCHEMBL20564967 | 0.83 | PTPN11 (0.53) | RIPK1KDM4ETP53 | |
| SCHEMBL15751660 | 0.83 | KDM4E (0.68) | RIPK1KDM4ECYP2C19SLC6A9TP53 | |
| SCHEMBL20152891 | 0.81 | RIPK1 (0.53) | RIPK1KDM4ECYP2C19HCRTR2SLC6A9 | |
| SCHEMBL23851037 | 0.79 | RIPK1 (0.51) | RIPK1KDM4ECYP2C19TP53DEGS1 | |
| SCHEMBL21868474 | 0.78 | KDM4E (0.60) | RIPK1KDM4ECYP2C19HCRTR2SIGMAR1 | |
| SCHEMBL3929507 | 0.75 | RIPK1 (0.46) | RIPK1KDM4ECYP2C19AOC3SIGMAR1 | |
| SCHEMBL29208663 | 0.74 | KDM4E (0.50) | RIPK1KDM4ETP53DEGS1 | |
| SCHEMBL13666598 | 0.73 | RIPK1 (0.44) | RIPK1KDM4ESIGMAR1 | |
| SCHEMBL18255043 | 0.73 | KDM4E (0.58) | KDM4ECYP2C19TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110913858-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2020-03-24 | — | — | CN | disclosed |